|
Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC). |
|
|
Honoraria - GlaxoSmithKline; Novartis; Pfizer |
Consulting or Advisory Role - Exelixis; GlaxoSmithKline; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Pfizer |
Travel, Accommodations, Expenses - Exelixis; GlaxoSmithKline; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Cerulean Pharma; Novartis |
Research Funding - Argos Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Eisai; Medivation; Novartis; Pfizer |
Research Funding - Argos Therapeutics; Eisai; Millennium; Novartis; Pfizer; TRACON Pharma |
|
|
Consulting or Advisory Role - Eisai; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Pfizer |
Speakers' Bureau - Astellas Pharma; Bayer Schering Pharma; GlaxoSmithKline; Novartis; Pfizer; Pierre Fabre |
Research Funding - Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
No Relationships to Disclose |